A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Acalabrutinib
Related studies linked through entity extraction aliases.
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
- Status
- COMPLETED
- Phase
- PHASE3
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
- Status
- COMPLETED
- Phase
- PHASE1
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2